Immunai, an AI biotech company specializing in mapping the human immune system, has joined forces with AstraZeneca for the development of a target for inflammatory bowel disease (IBD), which was identified through Immunai’s Immunodynamics Engine (IDE). Under the terms of the agreement, AstraZeneca will gain exclusive rights to develop and commercialize therapeutics directed at the target. Immunai will receive an upfront payment and is eligible to receive up to $85 million in total considerati...